PER

0.00%

10.5¢ percheron therapeutics limited

ThanksQS

First 53 Last

Share
Profile

Follow
Quay Street

478 Posts.

58

22/06/22

12:19

Post #: 62134819
Share

Originally posted by Vinceanna: ↑

Please refer to the attached ASX announcement:
ATL1102 License Agreement with Teva Pharmaceutical Industries Ltd. Dated 24-March 2010
http://www.aspecthuntley.com.au/asxdata/20100324/pdf/01049554.pdf

"Teva advised ANP that after performing certain steps in the development process, ATL1102 was determined to no longer be in line with Teva’s preferred product profile. ANP understands that business considerations or factors contributing to Teva’s decision include issues with one of the long-term toxicological studies that may require repeat of the study, lengthening the development time and time to market of the drug in light of the competitive landscape. "

From Taylor Collison Report Dated 27-Oct 2020
"ANP originally investigated ATL1102 as a treatment for multiple sclerosis (MS). ANP showed in a Phase II trial completed in 2008 that ATL1102 was effective in reducing the development of new lesions in MS patients.1 The efficacy was comparable to that of the marketed MS drug Tysabri, which targets the same VLA-4 pathway but via a different mechanism. ANP out-licenced ATL1102 to Teva in February 2008, but Teva returned the rights in March 2010, in part due to the need to conduct additional animal toxicology studies before progressing to the next stage of clinical development. ANP completed the additional animal safety studies but has not yet been able to attract another partner to fund further development of ATL1102 in MS. However, the company continues to explore opportunities to develop ATL1102 in this indication. "

Hope the above is clear.

Expand

Thanks
QS

ANP Price at posting: 9.1¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BUX

Buxton projects new graphite province discovery at WA Narryer play

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 34 more messages in this thread...

First 53 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 10.5¢		Change 0.000(0.00%)		Mkt cap ! $94.66M

Open	High	Low	Value	Volume
10.5¢	10.5¢	9.8¢	$58.09K	574.8K

Buyers (Bids)

No.	Vol.	Price($)
1	38503	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	194063	5

View Market Depth

No.	Vol.	Price($)
1	100000	0.099
2	108491	0.098
1	30927	0.097
1	10004	0.096
3	162157	0.095

Price($)	Vol.	No.
0.105	194063	5
0.110	254663	3
0.115	1334300	6
0.120	381142	9
0.125	110429	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

PER (ASX) Chart

ThanksQS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

ThanksQS

Top Stories

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News